8-K: Prestige Consumer Healthcare Exceeds Expectations in Q2, Reaffirms Full-Year Outlook

Prestige Consumer Healthcare reported second quarter results that surpassed expectations, driven by international growth and disciplined capital allocation, while reaffirming its full-year fiscal 2025 outlook.

Summary

• Prestige Consumer Healthcare announced its financial results for the second quarter and first half of fiscal year 2025, ending September 30, 2024.
• Second quarter revenue reached $283.8 million, slightly down 0.9% year-over-year, but ahead of expectations.
• The company's diluted earnings per share (EPS) for the quarter was $1.09, a 1.7% increase compared to the same period last year.
• EBITDA for the quarter was $91.9 million, a 4.0% decrease year-over-year, primarily due to the timing of costs.
• First-half revenue totaled $550.9 million, a 2.6% decrease compared to the first half of the previous fiscal year.
• First-half diluted EPS was $2.06, a 6.9% decrease compared to the prior year.
• The company generated $121.4 million in free cash flow in the first half of the fiscal year, a 14% increase year-over-year.
• Prestige Consumer Healthcare reaffirmed its full-year fiscal 2025 outlook, projecting revenue between $1,125 and $1,140 million, organic growth of approximately 1% excluding foreign exchange impacts, adjusted diluted EPS between $4.40 and $4.46, and free cash flow of $240 million or more.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the company exceeding expectations, reaffirming its full-year outlook, and demonstrating strong free cash flow generation. However, there are some concerns about supply chain issues and revenue declines in certain categories.

Positives

• The company's second quarter revenue exceeded expectations, driven by strong international growth.
• The company's diluted EPS increased by 1.7% in the second quarter compared to the prior year.
• Free cash flow generation was strong, with a 14% increase in the first half of the year.
• The company is actively managing its capital allocation, including debt reduction and share repurchases.
• The company's full-year outlook for revenue, earnings, and cash flow remains unchanged.
• The company experienced double-digit growth in eCommerce sales.
• The company's gross margin performance was stable at 55.1%.

Negatives

• Second quarter revenue decreased by 0.9% compared to the prior year.
• EBITDA for the second quarter decreased by 4.0% compared to the prior year due to the timing of costs.
• First-half revenue decreased by 2.6% compared to the prior year.
• First-half diluted EPS decreased by 6.9% compared to the prior year.
• The company experienced supply constraints for Clear Eyes, impacting revenue.
• The company saw declines in the Cough & Cold and Analgesic categories.

Risks

• The company faces potential supply chain challenges, particularly with Clear Eyes.
• The company is exposed to fluctuations in foreign exchange rates.
• The company is subject to competitive pressures in the consumer healthcare market.
• The company's performance is influenced by consumer trends and economic conditions.
• The company's ability to pass along rising costs to customers without impacting sales is a risk.

Future Outlook

The company reaffirmed its full-year fiscal 2025 outlook, projecting revenue between $1,125 and $1,140 million, organic growth of approximately 1% excluding foreign exchange impacts, adjusted diluted EPS between $4.40 and $4.46, and free cash flow of $240 million or more. The company expects earnings growth to accelerate as supply challenges subside.

Management Comments

• Ron Lombardi, Chief Executive Officer, stated that second quarter results exceeded sales and earnings expectations due to the strength of the company's diverse portfolio and disciplined capital deployment.
• Mr. Lombardi also noted that strong double-digit free cash flow growth enabled additional share repurchases and continued debt reduction.
• Management anticipates second half revenue growth building on first half momentum in the international segment and improvements in the Womens Health category.
• Management expects full-year adjusted EPS to be at the higher end of the outlook due to disciplined capital allocation and strong free cash flows.

Industry Context

The company operates in the consumer healthcare sector, which is influenced by factors such as consumer trends, competitive pressures, and supply chain dynamics. The company's focus on brand-building and international expansion aligns with broader industry trends.

Comparison to Industry Standards

• Prestige Consumer Healthcare's performance is comparable to other mid-sized consumer healthcare companies, such as Church & Dwight and Perrigo, which also focus on over-the-counter products.
• The company's international growth is a positive differentiator, as many competitors are more heavily focused on the North American market.
• The company's free cash flow generation is strong compared to industry averages, providing flexibility for capital allocation.
• The company's leverage ratio of 2.7x is within the range of acceptable levels for companies in this sector.

Stakeholder Impact

• Shareholders will benefit from the company's strong financial performance and capital allocation strategy.
• Employees will be impacted by the company's continued growth and success.
• Customers will benefit from the company's diverse portfolio of brands.
• Suppliers will be impacted by the company's supply chain management efforts.
• Creditors will be impacted by the company's debt reduction efforts.

Next Steps

• The company will continue to focus on brand-building and leveraging its cash generation.
• The company will continue to work with suppliers to address supply constraints for Clear Eyes.
• The company will continue to evaluate capital allocation options, including M&A, share buybacks, and debt reduction.

Key Dates

Keywords

Consumer Healthcare, Financial Results, Earnings, Revenue, EPS, EBITDA, Free Cash Flow, International Growth, Share Repurchase, Debt Reduction, Organic Growth, Supply Chain, Prestige Consumer Healthcare